This study examined the effect of SGLT2 inhibitors on symptoms of kidney disease in patients with Type 2 diabetes (T2D). The authors found that these agents helped lower the chance of developing kidney disease in these patients.

This study investigated if early changes in magnetic resonance imaging (MRI) can predict long-term response (LTR) to treatment in rheumatoid arthritis (RA). 

They found that MRI changes after 1 month of treatment can predict LTR to tofacitinib (Xeljanz).

This study evaluated the side effects in patients with type 2 diabetes (T2D) after treatment with glimepiride (Amaryl). The authors found that while glimepiride lowered mortality, the rate of most side effects was the same as other similar drugs.

This study looked at patients with diabetic foot ulcers that had not healed after standard wound care. This study found that topical oxygen significantly improved the healing rate of diabetic ulcers.

This study evaluated whether adding vildagliptin (Galvus) to metformin (Glucophage) could improve the duration of blood glucose control for patients with newly diagnosed Type 2 Diabetes (T2D). The authors found that this treatment combination improved long-term blood glucose control for these patients.

This study examined if glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs could reduce the rate of heart disease and stroke in patients with Type 2 diabetes (T2D). The authors found that fewer patients who received GLP-1RA drugs developed heart disease or stroke compared to those who received a placebo.

This study examined the effects of dapagliflozin (Forxiga) on blood magnesium levels in patients with type 2 diabetes (T2D). The authors concluded that dapagliflozin treatment helped improve blood magnesium levels in these patients.

This study explored whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) were effective in treating type-2 diabetes. The authors concluded that all GLP-1RA’s were effective and that the type of GLP-1RA chosen could be tailored to a patient’s specific needs.

This study is comparing the effectiveness of two insulin delivery systems for patients with type 1 diabetes (T1D). The authors concluded that the Diabeloop system was more effective and better reduced high blood glucose levels in these patients.

This study compared the effectiveness and safety of a closed-loop and sensor-augmented insulin pumps for patients with Type 1 diabetes (T1D). The authors found that the closed-loop device was more effective but had more side effects for these patients.